Unitedhealth Group INC

UnitedHealth Group reported strong second quarter 2026 results, exceeding expectations with revenues of $112.0 billion and earnings per share of $6.04, while also raising its full-year earnings outlook.

UnitedHealth Group shareholders re-elected all nine director nominees and ratified the appointment of Deloitte & Touche LLP at the 2026 Annual Meeting.

UnitedHealth Group announced that senior leadership will participate in an interview at the Bank of America Securities Health Care Conference on May 12, 2026.

UnitedHealth Group reported strong first quarter 2026 results, exceeding expectations with revenue growth and an increased full-year earnings outlook, while also detailing strategic initiatives and acquisitions.

UnitedHealth Group announced the appointment of Dennis Stankiewicz as its new Chief Accounting Officer, effective March 2, 2026, with Tom Roos transitioning to CFO of Optum Insight.

UnitedHealth Group Incorporated has amended a stock option granted to Stephen Hemsley, adding a two-year share holding requirement.

UnitedHealth Group reported steady Q1 2026 revenues with a 2% increase, driven by UnitedHealthcare's pricing and Optum Rx growth, though earnings from operations saw a slight dip due to segment performance and strategic investments.

UnitedHealth Group reported a 50% decline in third-quarter operating earnings and a 61% drop in net earnings attributable to common shareholders, primarily due to elevated medical cost trends and Medicare funding reductions.

UnitedHealth Group reports strong Q2 2025 revenue growth driven by Medicare Advantage and Optum Rx, despite elevated medical costs and funding pressures impacting earnings.

UnitedHealth Group's Q1 2025 results show revenue growth driven by UnitedHealthcare and Optum, with earnings impacted by Medicare Advantage funding and elevated care patterns.

UnitedHealth Group's third-quarter results show revenue growth offset by increased medical costs and significant losses from divestitures, alongside ongoing impacts from a major cyberattack.

UnitedHealth Group's second-quarter earnings were impacted by a cyberattack and losses from the sale of South American operations, despite revenue growth in key segments.

UnitedHealth Group Incorporated announced a significant decline in 2025 operating earnings, driven by elevated medical costs and substantial restructuring charges, despite overall revenue growth.

UnitedHealth Group's 2024 results reflect revenue growth offset by costs related to the Change Healthcare cyberattack and adjustments in Medicare Advantage funding.

UnitedHealth Group has granted performance-based and restricted stock units to executives, outlining vesting conditions, termination clauses, and restrictive covenants.

John H. Noseworthy, a Director at UnitedHealth Group, acquired 206 deferred stock units as part of his regular quarterly compensation.

Valerie Montgomery Rice, a Director at UnitedHealth Group, received 220 deferred stock units as compensation for her services.

Frederick William McNabb III, a Director at UnitedHealth Group, acquired 250 deferred stock units as part of his quarterly compensation.

Scott Gottlieb, a Director at UnitedHealth Group, acquired 210 shares of common stock through deferred stock units as part of his quarterly compensation.

Kristen Gil, a Director at UnitedHealth Group, acquired 206 deferred stock units as part of her quarterly compensation.

Paul R. Garcia, a Director at UnitedHealth Group, reported transactions involving the acquisition of common stock and deferred stock units.

UnitedHealth Group's 2026 proxy statement outlines leadership transitions, governance reforms, and executive compensation adjustments following shareholder feedback.

UnitedHealth Group urges shareholders to support its Say on Pay proposal, addressing concerns raised by ISS regarding the compensation package for incoming CEO Steve Hemsley.

UnitedHealth Group's upcoming annual meeting on June 3, 2024, will address director elections, executive compensation, auditor ratification, and a shareholder proposal on political contributions.

UnitedHealth Group's 2025 proxy statement outlines key proposals for the annual shareholder meeting, including director elections, executive compensation, and ratification of the independent auditor, while emphasizing the company's strategic growth priorities and commitment to improving the health system.

UnitedHealth Group's proxy statement announces the 2024 Annual Meeting of Shareholders and details the matters to be voted on, including the election of directors, executive compensation, and the ratification of the company's auditor.

UnitedHealth Group's 2024 proxy statement outlines key proposals for the annual shareholder meeting, including director elections, executive compensation, and responses to the Change Healthcare cyberattack.

Vanguard Capital Management reports beneficial ownership of 68,122,483 shares, representing 7.5% of UnitedHealth Group's common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G for UnitedHealth Group Inc., reporting zero beneficial ownership following an internal realignment where subsidiaries will now report separately.

The Vanguard Group has filed an amended Schedule 13G, reporting a 10.08% beneficial ownership stake in UnitedHealth Group Inc. as of April 30, 2025.